Scarica l'app Stockscreener
169.12
0.91%
-1.56
Dopo l'orario di chiusura:
169.20
0.08
+0.05%
Precedente Chiudi:
$170.68
Aprire:
$170.07
Volume 24 ore:
1.72M
Relative Volume:
0.86
Capitalizzazione di mercato:
$28.23B
Reddito:
$16.63B
Utile/perdita netta:
$1.39B
Rapporto P/E:
20.96
EPS:
8.0674
Flusso di cassa netto:
$2.12B
1 W Prestazione:
-5.37%
1M Prestazione:
-5.04%
6M Prestazione:
-23.34%
1 anno Prestazione:
+20.43%
Intervallo 1D:
$168.68
$173.35
Intervallo di 1 settimana:
$168.07
$179.73
Portata 52W:
$134.65
$247.04
Iqvia Holdings Inc Stock (IQV) Company Profile
Nome
Iqvia Holdings Inc
Settore
Industria
Telefono
919-998-2000
Indirizzo
2400 ELLIS ROAD, DURHAM, NC
Compare IQV vs TMO, DHR, IDXX, WAT, A
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IQV
Iqvia Holdings Inc
|
169.12 | 28.49B | 16.63B | 1.39B | 2.12B | 8.0674 |
TMO
Thermo Fisher Scientific Inc
|
438.34 | 166.56B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
161.91 | 116.46B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
528.79 | 42.03B | 4.45B | 1.10B | 1.06B | 13.59 |
WAT
Waters Corp
|
329.22 | 32.72B | 3.77B | 449.25M | 240.68M | 7.8556 |
A
Agilent Technologies Inc
|
111.70 | 32.01B | 7.07B | 1.29B | 993.00M | 4.5355 |
Iqvia Holdings Inc Stock (IQV) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-09 | Aggiornamento | TD Cowen | Hold → Buy |
| 2026-03-06 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2026-03-03 | Iniziato | RBC Capital Mkts | Outperform |
| 2025-12-02 | Ripresa | Morgan Stanley | Overweight |
| 2025-11-13 | Iniziato | BMO Capital Markets | Outperform |
| 2025-11-03 | Downgrade | TD Cowen | Buy → Hold |
| 2025-10-29 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2025-10-09 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2025-09-09 | Aggiornamento | Jefferies | Hold → Buy |
| 2025-04-25 | Downgrade | HSBC Securities | Buy → Hold |
| 2025-04-10 | Downgrade | Barclays | Overweight → Equal Weight |
| 2025-02-03 | Downgrade | BTIG Research | Buy → Neutral |
| 2024-12-20 | Iniziato | Stephens | Overweight |
| 2024-10-14 | Iniziato | Redburn Atlantic | Buy |
| 2024-09-04 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-07-24 | Downgrade | Jefferies | Buy → Hold |
| 2024-06-06 | Iniziato | Goldman | Buy |
| 2024-02-26 | Iniziato | Leerink Partners | Outperform |
| 2024-02-15 | Downgrade | Guggenheim | Buy → Neutral |
| 2024-02-13 | Iniziato | BTIG Research | Buy |
| 2023-11-02 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2023-09-06 | Iniziato | HSBC Securities | Buy |
| 2023-03-17 | Iniziato | Truist | Buy |
| 2022-12-06 | Iniziato | Cowen | Outperform |
| 2022-11-17 | Downgrade | Citigroup | Buy → Neutral |
| 2022-08-25 | Iniziato | Credit Suisse | Outperform |
| 2022-07-15 | Iniziato | SVB Leerink | Outperform |
| 2022-05-24 | Iniziato | Guggenheim | Buy |
| 2022-04-29 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-04-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2021-08-05 | Ripresa | Credit Suisse | Outperform |
| 2021-04-16 | Aggiornamento | Stephens | Equal-Weight → Overweight |
| 2021-03-08 | Aggiornamento | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2021-03-03 | Iniziato | Barclays | Overweight |
| 2020-07-07 | Iniziato | Stephens | Equal-Weight |
| 2020-03-02 | Iniziato | Deutsche Bank | Buy |
| 2020-01-08 | Iniziato | Wells Fargo | Overweight |
| 2020-01-07 | Iniziato | Citigroup | Buy |
| 2019-12-13 | Aggiornamento | CFRA | Sell → Hold |
| 2019-11-14 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2019-06-21 | Aggiornamento | Mizuho | Neutral → Buy |
| 2019-05-28 | Iniziato | SVB Leerink | Outperform |
| 2019-01-18 | Aggiornamento | Jefferies | Hold → Buy |
| 2018-10-09 | Iniziato | UBS | Buy |
| 2018-10-02 | Reiterato | Robert W. Baird | Outperform |
| 2018-07-25 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2018-07-25 | Reiterato | Stifel | Buy |
| 2018-07-03 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2018-04-13 | Aggiornamento | Goldman | Neutral → Buy |
| 2018-03-07 | Aggiornamento | SunTrust | Hold → Buy |
| 2018-01-19 | Iniziato | Evercore ISI | Outperform |
Mostra tutto
Iqvia Holdings Inc Borsa (IQV) Ultime notizie
Is There Now An Opportunity In IQVIA Holdings Inc. (NYSE:IQV)? - Moomoo
Analysts Offer Insights on Healthcare Companies: IQVIA Holdings (IQV), BeOne Medicines (ONC) and Nektar Therapeutics (NKTR) - The Globe and Mail
Will IQVIA's (IQV) AI‑Driven Biosimilar Partnership with Kexing Reshape Its Long‑Term Narrative? - Yahoo Finance
IQVIA Holdings earnings preview: What to expect - MSN
BofA Securities Maintains IQVIA Holdings(IQV.US) With Buy Rating, Maintains Target Price $245 - Moomoo
IQVIA Holdings stock (US46266C1053): Expands AI-powered biosimilars deal with Kexing Biopharm - AD HOC NEWS
IQVIA Holdings, Inc. Common Stock (NY: IQV - FinancialContent
IQVIA expands collaboration with Kexing Biopharm on biosimilars - Investing.com UK
Why (IQV) Price Action Is Critical for Tactical Trading - Stock Traders Daily
IQVIA expands collaboration with Kexing Biopharm on biosimilars By Investing.com - Investing.com Nigeria
IQVIA Holdings Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
AI-powered trials to speed global biosimilar drugs in IQVIA-Kexing pact - Stock Titan
IQVIA Holdings stock (US46266C1053): Global leader in healthcare data analytics - AD HOC NEWS
IQVIA Q1 2026 slides: earnings beat drives guidance raise By Investing.com - Investing.com Canada
IQVIA Q1 2026 slides: earnings beat drives guidance raise - Investing.com
Earnings call transcript: IQVIA surpasses Q1 2026 forecasts, stock surges - Investing.com
Earnings call transcript: IQVIA surpasses Q1 2026 forecasts, stock surges By Investing.com - Investing.com Australia
IQVIA’s Q1 Earnings Call: Our Top 5 Analyst Questions - Barchart.com
IQVIA Holdings Inc. stock outperforms competitors on strong trading day - MSN
IQVIA (NYSE: IQV) director granted 171 deferred shares at $178.64 - Stock Titan
IQVIA (NYSE: IQV) director Colleen Goggins receives 214 Deferred Shares grant - Stock Titan
IQVIA (NYSE: IQV) director Jim Fasano receives 228 deferred share award - Stock Titan
IQVIA (NYSE: IQV) director awarded 185 deferred shares with 1:1 common conversion - Stock Titan
IQVIA Holdings Inc. stock underperforms Monday when compared to competitors - MarketWatch
Why is Larry Robbins Bullish on IQVIA Holdings (IQV) Amid Market Volatility - Kavout
IQVIA Holdings Inc. (IQV): Larry Robbins Is Bullish on This Stock - Insider Monkey
Why IQVIA Holdings (IQV) Is Up 12.8% After Q1 Beat and Bigger Buyback Plan – And What's Next - Sahm
Dark Horse Consulting Group and KunTuo Announce Memorandum of Understanding Providing Cell and Gene Therapy Developers with an Accelerated Path to Clinical Development in China - GlobeNewswire Inc.
IQVIA Holdings, Inc. (IQV) Stock Analysis: Robust Growth Potential With A 27.92% Upside - DirectorsTalk Interviews
IQVIA Q1 Earnings Call Highlights - sharewise.com
Here's why you should retain IQV stock in your portfolio now - MSN
IQVIA Holdings stock (US46266C1053): Data?driven healthcare analytics in focus for US investors - AD HOC NEWS
IQVIA board authorizes additional $2B in share repurchases - MSN
IQVIA Expands Share Repurchase Authorization by $2 Billion - The Globe and Mail
BMO Capital Maintains IQVIA Holdings(IQV.US) With Buy Rating, Maintains Target Price $210 - Moomoo
IQVIA Holdings Inc. (NYSE:IQV) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year - simplywall.st
IQVIA Holdings | 8-K: Current report - Moomoo
Earnings Update: IQVIA Holdings Inc. (NYSE:IQV) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts - Yahoo Finance
IQVIA Increases Share Repurchase Authorization by $2 Billion, Bringing Total to $3.2 Billion 1 - Minichart
Artificial Intelligence in Epidemiology Market Is Going - openPR.com
IQVIA Board of Directors Approves $2 Billion Increase in Share Repurchase Authorization - The National Law Review
IQVIA Board Approves $2B Increase to Share Repurchase Authorization, $3.2B Remaining - TradingView
IQVIA board authorizes additional $2 billion stock buyback - Investing.com
IQVIA board authorizes additional $2 billion stock buyback By Investing.com - Investing.com Australia
IQVIA (NYSE: IQV) boosts buyback plan, $3.2B now authorized - Stock Titan
Iqvia Holdings Inc Azioni (IQV) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
5.36%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):